Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference

Oncogene volume 22, pages 8653–8661 (2003)Cite this article

Abstract

Cyclooxygenases, particularly COX-2, play an important role in tumor development and progression. We have previously shown that COX-2 expression is an independent prognostic factor in human ovarian carcinoma. In this study, we investigated the effects of the inhibition of COX isoforms by the NSAID NS-398 as well as by COX-isoform-specific RNA interference (RNAi) in the human ovarian carcinoma cell lines OVCAR-3 and SKOV-3. OVCAR-3 cells showed a constitutive expression of COX-1 and an induction of high levels of COX-2 and PGE2 after stimulation with interleukin-1β. In contrast, SKOV-3 cells were negative for both COX isoforms. In OVCAR-3 cells, PGE2 production was inhibited by NS-398 in concentrations of 1 μ M and by a COX-2-specific silencing RNA (siRNA), while a COX-1-specific siRNA did not have an effect. This suggests that COX-2 is the major source of PGE2 in this cell line. To dissociate COX-2-specific and non-COX-2-specific effects on cell proliferation, a proliferation assay was performed after incubation of cells with NS-398 and COX siRNAs. NS-398 induced an inhibition of cell proliferation at concentrations of 50–500 μ M, which are above the concentrations needed for the inhibition of PGE2 production. This inhibitory effect was present in the COX-positive cell line OVCAR-3 as well as in the COX-negative cell line SKOV-3 and could not be reverted by addition of exogenous PGE2. Neither COX-1- nor COX-2-specific siRNAs had an effect on cell proliferation of OVCAR-3 cells. Cell cycle analysis showed an increased accumulation of cells in the G0/G1 phase after treatment with NS-398, but not with COX siRNAs. These experiments suggest that NS-398 reduced cell proliferation in ovarian carcinoma cells by induction of G0/G1 cell cycle arrest independent of COX-2 inhibition. Our study shows that specific inhibition of COX isoforms by RNAi could be used to dissociate effects of NSAIDs. Furthermore, our results suggest that cell cycle arrest is one of the primary mechanisms responsible for the antiproliferative effects of NS-398 on ovarian carcinoma cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

Abbreviations

COX:

cyclooxygenase

PG:

prostaglandin

NSAID:

nonsteroidal anti-inflammatory drug

XTT:

2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt

References

  • Caplen N, Parrish S, Farhad I, Fire A and Morgan RA . (2001). Proc. Natl. Acad. Sci. USA, 98, 9742–9747.

  • Denkert C, Köbel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B and Hauptmann S . (2002). Am. J. Pathol., 60, 893–903.

  • Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T . (2001). Nature, 411, 494–498.

  • Elbashir SM, Harborth J, Weber K and Tuschl T . (2002). Methods, 26, 199–213.

  • Elder DJ, Halton DE, Hague A and Paraskeva C . (1997). Clin. Cancer Res., 3, 1679–1683.

  • Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G and Ranelletti FO . (2002a). J. Clin. Oncol., 20, 973–981.

  • Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO and Scambia G . (2002b). Ann. Oncol., 13, 1205–1211.

  • Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Melo CC . (1998). Nature, 391, 806–811.

  • Fogh J . (1975). Human Tumor Cells In Vitro. Plenum Press: New York, pp. 115–159.

    Google Scholar 

  • Goldberg Y, Nassif I, Pittas A, Tsai LL, Dynlacht BD, Rigas B and Steven JS . (1996). Oncogene, 12, 893–901.

  • Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR and Ozols RF . (1983). Cancer Res., 43, 5379–5389.

  • Harborth J, Elbashir SM, Bechert K, Tuschl T and Weber K . (2001). J. Cell Sci., 114, 4557–4565.

  • Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollmann J, Herschman H and Dubinett SM . (1998). Cancer Res., 58, 1208–1216.

  • Hung WC, Chang HC, Pan MR, Lee TH and Chuang LY . (2000). Mol. Pharmacol., 58, 1398–1403.

  • Khuder SA and Mutgi AB . (2001). Br. J. Cancer, 84, 1188–1192.

  • Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C . (1991). J. Immunol. Methods, 139, 271–279.

  • O'Banion MK, Winn VD and Young DA . (1992). Proc. Natl. Acad. Sci. USA, 89, 4888–4892.

  • Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM . (1996). Cell, 87, 803–809.

  • Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J . (2002). Cancer Res., 62, 632–635.

  • Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myeers RB, Talley LI, Partridge EE and Grizzle WE . (2002). Clin. Cancer Res., 8, 202–209.

  • Shono T, Tofilon PJ, Bruner JM, Owolabi O and Lang FF . (2001). Cancer Res., 61, 4375–4381.

  • Thompson HJ, Briggs S, Paranka NS, Piazza GA, Brendel K, Gross PH, Sperl GJ, Pamukcu R and Ahnen DJ . (1995). J. Natl. Cancer Inst., 87, 1259–1260.

  • Thun MJ . (1994). Cancer Metast. Rev., 13, 269–277.

  • Toyoshima T, Kamijo R, Takizawa K, Sumitani K, Ito D and Nagumo M . (2002). Br. J. Cancer, 86, 1150–1156.

  • Tsujii M and DuBois RN . (1995). Cell, 83, 493–501.

  • Tsujii M, Kawano S and DuBois RN . (1997). Proc. Natl. Acad. Sci. USA, 94, 3336–3340.

  • Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M and DuBois RN . (1998). Cell, 93, 705–716.

  • Warner TD, Giuliano F, Vojnovic I, Busaka A, Mitchell JA and Vane JR . (1999). Proc. Natl. Acad. Sci. USA, 96, 7563–7568.

  • Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS and Sweeney CJ . (2000). Carcinogenesis, 21, 139–146.

  • Yip-Schneider M, Sweeney CJ, Jung SH, Crowell PL and Marshall MS . (2001). J. Pharmacol. Exp. Therap., 298, 976–985.

  • Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T and Wada S . (2000). Cancer, 89, 589–566.

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, Charité Hospital, Humboldt University, Campus Mitte, Schumannstr. 20/21, Berlin, D-10117, Germany

    Carsten Denkert, Antje Fürstenberg, Ines Koch, Martin Köbel, Wilko Weichert & Antje Siegert

  2. Department of Hematology, Oncology and Tumor Immunology, Charité-Campus Berlin-Buch, Humboldt University, Berlin-Buch, D-13125, Germany

    Peter Ted Daniel

  3. Institute of Pathology, Martin-Luther University Halle-Wittenberg, Halle, Germany

    Steffen Hauptmann

Authors
  1. Carsten Denkert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antje Fürstenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Ted Daniel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ines Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Köbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wilko Weichert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antje Siegert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Steffen Hauptmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten Denkert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Denkert, C., Fürstenberg, A., Daniel, P. et al. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 22, 8653–8661 (2003). https://doi.org/10.1038/sj.onc.1206920

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206920

Keywords

This article is cited by

Search

Advanced search

Quick links